Peripheral vascular disease articles


One Year of Successful Carotid Artery Stenting with the CGuard Device

One Year of Successful Carotid Artery Stenting with the CGuard Device

This registry of daily clinical practice suggests that this specifically designed double-mesh carotid stent is safe and associated with a minimal and acceptable occurrence of neurological events up to 12 months of follow-up. This double-mesh stent has already been tested, and its short- and long-term efficacy has been proven. However, more recent data have challenged the

SOLACI-CACI 2021 Virtual

SOLACI-CACI 2021 | Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm Session

✔️ Watch again the Session on “Complex Pulmonary Hypertension and Aortic Endovascular Aneurysm” in the SOLACI-CACI 2021 Congress. 👨‍🏫 Program: SESSION I: Chronic Thromboembolic Pulmonary Hypertension 02:48 – Definition, epidemiology, diagnostic algorithm and pharmacological treatment. – Pedro Trujillo 16:27 – Invasive Endovascular Strategies in Chronic PTE: Pulmonary Angioplasty – Fabio Solano 30:13 – Surgical Thromboendarterectomy.

tavi funcion cognitiva

Asymptomatic Carotid Lesions and Cognitive Impairment: Does Intervention Play a Role?

This study was designed to determine the effect of carotid endarterectomy/angioplasty on early (baseline vs. 3 months) and late (baseline vs. >5 months) cognitive function in patients with asymptomatic lesions. This systematic research included 31 non-randomized studies. Regarding the immediate post-operative period, 24 of these papers reported significant improvement in cognitive function; one study reported significant deterioration;

ESC 2021 | ACST-2: CAS vs endarterectomía en pacientes asintomáticos

ESC 2021 | ACST-2: CAS vs Endarterectomy in Asymptomatic Patients

The ACST-2 was designed to compare long-term outcomes of carotid artery stenting (CAS) vs carotid endarterectomy (CEA) in patients with asymptomatic stenosis.  Prior to this study we had the German registry including 18,000 patients undergoing CAS and 86,000 receiving CEA between 2014 and 2019. At 30 days, disabling stroke rate was 0.7% for both strategies.

endoprotesis fenestradas

Fenestrated Endografts as Treatment for Type I Endoleak: What is the Price of Success?

Both fenestrated and branched endografts are effective to treat patients after failure of their initial endograft due to significant type I endoleak. This situation is costly both because of the devices themselves, and also due to the several endovascular and surgical procedures required. Failure of an endograft to treat an infrarenal abdominal aortic aneurysm due to

SOLACI PERIPHERAL | Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection

Here is a new SOLACI PERIPHERAL Case! In this opportunity, Dr. Daniel Zanuttini (Arg.) presents “Type Ib Endoleak Correction in Patient After Minimally Invasive Hybrid Treatment in Type A Aortic Disection”. This is the 8th clinical case presented by SOLACI Peripheral. The purpose of this space is to encourage and further the exchange of experiences

Programas de ejercicios en la enfermedad vascular periférica

Discrepancy between Angina and Ischemia Repeats in Peripheral Artery Disease

Three randomized studies showed exercising significantly improves 6-minute walk outcomes in patients with peripheral artery disease (PAD). However, many participants randomized to exercise did not perceive changes, and sometimes even got worse.  These findings suggest a significant discrepancy between objective and perceived change in walking ability among PAD patients.   400 patients with peripheral artery disease

El tratamiento endovascular parece superior a la cirugía en aneurismas rotos

Abdominal Aortic Aneurysm during the Pandemic: Should They Be Operated or Deferred?

Some European societies have recommended deferring the treatment of infrarenal abdominal aortic aneurysm (AAA) ≥5.5 cm during the COVID-19 pandemic. However, these documents have also suggested optimal deferral times, and everything must be adjusted according to the transmission risk/risk of rupture balance. Annual risk of rupture can be estimated based on a prospective cohort published by

SOLACI PERIPHERAL | 7th Clinical Case: Percutaneous Treatment for Nutcracker Syndrome

New SOLACI PERIPHERAL clinical case to keep learning among peers! Dr. Carlos Eduardo Díniz Couto shares a “Nutcracker” case from Belo Horizonte, Brazil. This is the 7th clinical case presented by SOLACI Peripheral on the SOLACI website. This space is intended to further promote and share experiences and opinions in order to continue improving our

Subutilización del tratamiento médico en enfermedad vascular periférica

Which Type 2 Endoleaks Should We Intervene?

This work emphasizes the need to be conservative with type 2 endoleaks, and the need for long-term prospective information to learn about the advantages of intervention. The presence of type 2 endoleaks is associated with reintervention, as it was historically assumed that they increase the risk of sac rupture. However, this new research, published in

ELUVIA: DES en territorio femoropoplíteo con lesiones complejas

ELUVIA: DES in Complex Femoropopliteal Lesions

Paclitaxel-eluting stent Eluvia showed promising results after two years with a revascularization freedom rate of 80% despite the fact that these were complex femoropopliteal lesions. As the safety of paclitaxel-eluting devices becomes more consistent, more studies on its efficacy are being published. Back in 2018, the safety of paclitaxel-eluting balloons and stents was under scrutiny